Ramon, 1926, Ann. Inst. Pasteur, 40, 1
10.1016/j.imlet.2005.08.002
10.1016/j.vaccine.2005.01.116
10.1016/S0264-410X(98)00179-0
10.1016/0264-410X(86)90005-8
10.1111/j.1600-065X.1995.tb00075.x
10.4049/jimmunol.165.10.5780
10.1517/14712598.4.7.1129
10.1517/13543784.7.9.1475
Garçon N, Van Mechelen M, Wettendorff M. Development and evaluation of AS04, a novel and improved immunological adjuvant system containing MPL and aluminium salt. In:Immunopotentiators in Modern Vaccines.Schijns V, O’Hagan D (Eds). Elsevier Academic Press, London, UK 161–177 (2006).
10.1016/S0168-8278(03)00213-7
10.1111/j.1523-1755.2005.00689.x
10.1016/j.vaccine.2006.06.005
10.1016/j.jadohealth.2007.02.015
10.1016/S0140-6736(06)68439-0
10.1016/S0140-6736(04)17398-4
Gall SA, Teixeira J, Wheeler Cet al. Substantial impact on precancerous lesions and HPV infections through 5.5 years in women vaccinated with the HPV-16/18 L1 VLP AS04 candidate vaccine.98th Annual Meeting of the American Association for Cancer Research.April 14–18 Los Angeles, CA, USA (2007) (Abstract 4900).
10.1016/S0140-6736(07)60946-5
10.1016/j.pharmthera.2006.04.008
10.1093/oxfordjournals.aje.a120954
10.1093/oxfordjournals.aje.a120955
10.1128/jvi.70.5.2852-2860.1996
10.1128/jvi.68.8.5321-5325.1994
10.1016/S0264-410X(00)00417-5
10.1128/JVI.74.22.10287-10292.2000
10.1111/j.1600-065X.1999.tb01328.x
Gu, 1995, Dev. Biol. Stand., 84, 171
Sokal, 2007, J. Infect. Dis.
10.1016/S0264-410X(99)00566-6
Boland G, Beran J, Lievens Met al. Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04.Vaccine23(3), 316–320 (2004).
10.1016/S0264-410X(02)00397-3
10.1016/j.vaccine.2007.04.008
10.1016/S0264-410X(97)00254-5
10.1016/S0264-410X(96)00293-9
10.1056/NEJM199701093360202
10.4269/ajtmh.1999.61.865
10.1016/S0140-6736(01)06957-4
10.1016/S0140-6736(04)17223-1
10.1016/S0140-6736(05)67669-6
10.1111/j.1365-2249.2004.02371.x
10.1016/j.vaccine.2004.01.031
10.4049/jimmunol.171.12.6961
10.1016/j.vaccine.2004.07.023
Ockenhouse CF, Angov E, Kester KEet al. Phase I safety and immunogenicity trial of FMP1/AS02A, aPlasmodium falciparumMSP-1 asexual blood stage vaccine.Vaccine24(15), 3009–3017 (2006).
10.1371/journal.pctr.0010032
10.1093/clinids/11.Supplement_2.S353
10.1001/jama.1994.03510330076038
10.4049/jimmunol.172.12.7618
10.1128/IAI.74.4.2392-2401.2006
Leroux-Roels, Medical and Health in the Tropics.
10.1016/j.vaccine.2005.03.003
10.1016/j.vaccine.2004.11.051
10.1016/j.vaccine.2004.11.034
10.1097/00002030-199805000-00002
10.1128/JVI.77.2.1049-1058.2003
10.1016/j.vaccine.2006.07.050
10.1016/S0959-8049(02)00479-3
10.1097/00002371-200403000-00006
10.4049/jimmunol.172.5.3289
10.1016/j.vaccine.2007.03.012
10.1371/journal.pctr.0010034
Macete, 2007, Trop. Med. Int. Health, 12, 37, 10.1111/j.1365-3156.2006.01754.x
10.1016/j.vaccine.2006.06.033
10.1016/j.micinf.2005.03.011
